TCA
CRL icon

Trifecta Capital Advisors’s Charles River Laboratories CRL Stock Holding History

Trifecta Capital Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3
Closed -$452 – 483
2025
Q1 		$452 Hold
3
– – ﹤0.01% 409
2024
Q4 		$554 Hold
3
– – ﹤0.01% 398
2024
Q3 		$591 Hold
3
– – ﹤0.01% 400
2024
Q2 		$620 Hold
3
– – ﹤0.01% 404
2024
Q1 		$813 Hold
3
– – ﹤0.01% 387
2023
Q4 		$710 Hold
3
– – ﹤0.01% 421
2023
Q3 		$588 Hold
3
– – ﹤0.01% 412
2023
Q2 		$631 Hold
3
– – ﹤0.01% 406
2023
Q1 		$606 Hold
3
– – ﹤0.01% 410
2022
Q4 		$654 Buy
+3
New +$655 ﹤0.01% 409

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Trifecta Capital Advisors's CRL Position: Q2 2025 in Review

Trifecta Capital Advisors sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 3 shares — an estimated $452 sold.

Trifecta Capital Advisors first reported a position in CRL in Q4 2022 and held it in 10 quarters. The position peaked at $813 in Q1 2024. 519 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

  • Trifecta Capital Advisors reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
  • Trifecta Capital Advisors sold 3 Charles River Laboratories shares in Q2 2025, an estimated $452.
  • Trifecta Capital Advisors first reported a position in Charles River Laboratories in Q4 2022 and held it in 10 quarters.
  • Trifecta Capital Advisors's Charles River Laboratories position peaked at $813 in Q1 2024.
  • 519 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on Trifecta Capital Advisors's 13F filing for Q2 2025, filed 23 Jul 2025.